乙酰半胱氨酸增加了不同酶耐药性的头孢他啶-阿维巴坦耐药肠杆菌科对头孢他啶-阿维巴坦的体外和体内敏感性。
Acetylcysteine increases sensitivity of ceftazidime-avibactam-resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo.
机构信息
Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Department of Medical Lab Science, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
出版信息
BMC Microbiol. 2023 Nov 3;23(1):321. doi: 10.1186/s12866-023-03068-5.
BACKGROUND
Ceftazidime-avibactam (CZA) improves treatment outcomes for infections caused by carbapenem-resistant organisms, but has led to serious bacterial resistance. Acetylcysteine (NAC) is an approved medication that protects the respiratory tract through antioxidant and anti-inflammatory effects.
RESULTS
This study found that NAC combined with CZA effectively inhibits the growth of CZA-resistant clinical Enterobacterales strains. The CZA/NAC combination inhibits biofilm formation in vitro and decreases bacterial burden in a mouse thigh infection model. The combination is biocompatible and primarily increases cell membrane permeability to cause bacterial death.
CONCLUSIONS
These findings prove that the CZA/NAC combination has potential as a treatment for CZA-resistant Enterobacterales infections.
背景
头孢他啶-阿维巴坦（CZA）改善了由耐碳青霉烯类药物的病原体引起的感染的治疗效果，但也导致了严重的细菌耐药性。乙酰半胱氨酸（NAC）是一种已批准的药物，通过抗氧化和抗炎作用保护呼吸道。
结果
本研究发现，NAC 与 CZA 联合使用可有效抑制 CZA 耐药的临床肠杆菌科菌株的生长。CZA/NAC 联合抑制体外生物膜形成，并减少小鼠大腿感染模型中的细菌负荷。该联合具有生物相容性，主要通过增加细胞膜通透性导致细菌死亡。
结论
这些发现证明 CZA/NAC 联合具有治疗 CZA 耐药肠杆菌科感染的潜力。
Zotero 插件